Bormioli Pharma
Bormioli Pharma, a leading name in the pharmaceutical packaging industry, is headquartered in Italy and operates extensively across Europe and beyond. Founded in 1927, the company has established itself as a pioneer in the design and production of glass and plastic containers, primarily serving the pharmaceutical, healthcare, and cosmetic sectors. Bormioli Pharma is renowned for its innovative solutions, including high-quality vials, bottles, and closures that ensure product safety and integrity. The company’s commitment to sustainability and advanced manufacturing processes sets it apart in a competitive market. With a strong focus on research and development, Bormioli Pharma has achieved significant milestones, solidifying its position as a trusted partner for global pharmaceutical companies.
DitchCarbon Score
How does Bormioli Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Paper Products industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Bormioli Pharma's score of 30 is higher than 62% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Bormioli Pharma's reported carbon emissions
In 2023, Bormioli Pharma reported total carbon emissions of approximately 134,185,000 kg CO2e for Scope 1 and 2, and about 95,334,000 kg CO2e for Scope 3 emissions. The Scope 3 emissions breakdown includes significant contributions from purchased goods and services (about 61,598,000 kg CO2e) and downstream transportation and distribution (approximately 11,428,000 kg CO2e). Comparatively, in 2022, the company recorded Scope 1 and 2 emissions of around 126,655,000 kg CO2e and Scope 3 emissions of about 84,536,000 kg CO2e. This indicates a slight increase in emissions across both scopes year-on-year. Bormioli Pharma has set ambitious reduction targets, aiming for a 30% reduction in CO2 emissions for both Scope 1 and Scope 2 by 2030, compared to 2021 levels. This commitment reflects the company's proactive approach to climate action and aligns with industry standards for sustainability. The emissions data is cascaded from its parent company, Bormioli Pharma S.p.a., which is part of the Gerresheimer AG corporate family. This relationship underscores the importance of collaborative efforts in achieving climate goals across subsidiaries. Overall, Bormioli Pharma's emissions and climate commitments demonstrate a clear focus on reducing their carbon footprint while navigating the complexities of their operational impacts.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | 68,498,000 | - | - | - |
| Scope 2 | 47,440,000 | - | - | - |
| Scope 3 | - | - | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Bormioli Pharma is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
